Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Meta-Analysis

Pre-Admission Beta-Blocker Therapy and Outcomes of Coronavirus Disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression

Author(s): Timotius Ivan Hariyanto, Joshua Edward Hananto, Denny Intan and Andree Kurniawan*

Volume 22, Issue 2, 2022

Published on: 13 July, 2022

Page: [104 - 117] Pages: 14

DOI: 10.2174/1871529X22666220420112735

Price: $65

Abstract

Background: Hypertension and heart failure are known risk factors for coronavirus disease 2019 (COVID-19) severity and mortality outcomes. Beta-blocker is one of the drugs of choice to treat these conditions. The purpose of this study is to explore the relationship between preadmission beta-blocker use and COVID-19 outcomes.

Methods: PubMed and Europe PMC were used as the database for our search strategy by using combined keywords related to our aims until December 10th, 2020. All articles related to COVID- 19 and beta-blocker were retrieved. Review Manager 5.4 and Comprehensive Meta-Analysis 3 software were used to perform statistical analysis.

Results: A total of 43 studies consisting of 11,388,556 patients were included in our analysis. Our meta-analysis showed that the use of beta-blocker was associated with increased risk of COVID-19 [OR 1.32 (95% CI 1.02 - 1.70), p = 0.03, I2 = 99%, random-effect modelling], clinical progression [OR 1.37 (95% CI 1.01 - 1.88), p = 0.04, I2 = 89%, random-effect modelling], and mortality from COVID-19 [OR 1.64 (95% CI 1.22 - 2.19), p = 0.0009, I2 = 94%, random-effect modelling]. Metaregression showed that the association with mortality outcome were influenced by age (p = 0.018) and hypertension (p = 0.005).

Conclusion: The risk and benefits of using beta-blocker as a drug of choice to treat hypertensive patients should be considered and reviewed individually, case by case, knowing their association with higher incidence and severity of COVID-19 infections. Other first-line antihypertensive drugs may be considered as an alternative therapy if the risk of administering beta blockers outweighs the benefits of COVID-19 infection. Registration details: PROSPERO (CRD42021260455).

Keywords: Coronavirus disease 2019, beta-blocker, hypertension, heart failure, cardiovascular, treatment.

Next »
[1]
Kwenandar, F.; Japar, K.V.; Damay, V.; Hariyanto, T.I.; Tanaka, M.; Lugito, N.P.H.; Kurniawan, A. Coronavirus disease 2019 and cardiovascular system: A narrative review. Int. J. Cardiol. Heart Vasc., 2020, 29, 100557.
[http://dx.doi.org/10.1016/j.ijcha.2020.100557] [PMID: 32550259]
[2]
Hariyanto, T.I.; Putri, C.; Hananto, J.E.; Arisa, J.; Fransisca, V.; Situmeang, R.; Kurniawan, A. Delirium is a good predictor for poor outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression. J. Psychiatr. Res., 2021, 142, 361-368.
[http://dx.doi.org/10.1016/j.jpsychires.2021.08.031] [PMID: 34425488]
[3]
Zuin, M.; Rigatelli, G.; Zuliani, G.; Rigatelli, A.; Mazza, A.; Roncon, L. Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis. J. Infect., 2020, 81(1), e84-e86.
[http://dx.doi.org/10.1016/j.jinf.2020.03.059] [PMID: 32283158]
[4]
Ssentongo, P.; Ssentongo, A.E.; Heilbrunn, E.S.; Ba, D.M.; Chinchilli, V.M. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One, 2020, 15(8), e0238215.
[http://dx.doi.org/10.1371/journal.pone.0238215] [PMID: 32845926]
[5]
Hariyanto, T.I.; Kurniawan, A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis. Sleep Med., 2021, 82, 47-53.
[http://dx.doi.org/10.1016/j.sleep.2021.03.029] [PMID: 33892451]
[6]
Hariyanto, T.I.; Intan, D.; Hananto, J.E.; Putri, C.; Kurniawan, A. Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Diabetes Res. Clin. Pract., 2021, 179, 109031.
[http://dx.doi.org/10.1016/j.diabres.2021.109031] [PMID: 34461139]
[7]
Hariyanto, T.I.; Rosalind, J.; Christian, K.; Kurniawan, A. Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis. South. Afr. J. HIV Med., 2021, 22(1), 1220.
[http://dx.doi.org/10.4102/sajhivmed.v22i1.1220] [PMID: 33936793]
[8]
Hariyanto, T.I.; Kurniawan, A. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: A systematic review, meta-analysis, and meta-regression. J. Diabetes Metab. Disord., 2021, 20(1), 543-550.
[http://dx.doi.org/10.1007/s40200-021-00777-4] [PMID: 33816358]
[9]
Siahaan, Y.M.T.; Ketaren, R.J.; Hartoyo, V.; Hariyanto, T.I. Epilepsy and the risk of severe coronavirus disease 2019 outcomes: A systematic review, meta-analysis, and meta-regression. Epilepsy Behav., 2021, 125, 108437.
[http://dx.doi.org/10.1016/j.yebeh.2021.108437] [PMID: 34839246]
[10]
Hariyanto, T.I.; Halim, D.A.; Jodhinata, C.; Yanto, T.A.; Kurniawan, A. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin. Exp. Pharmacol. Physiol., 2021, 48(6), 823-830.
[http://dx.doi.org/10.1111/1440-1681.13488] [PMID: 33719081]
[11]
Hariyanto, T.I.; Hardyson, W.; Kurniawan, A. Efficacy and safety of tocilizumab for coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Drug Res. (Stuttg.), 2021, 71(5), 265-274.
[http://dx.doi.org/10.1055/a-1336-2371] [PMID: 33401328]
[12]
Hariyanto, T.I.; Halim, D.A.; Rosalind, J.; Gunawan, C.; Kurniawan, A. Ivermectin and outcomes from COVID-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies. Rev. Med. Virol., 2021, (2), e2265.
[http://dx.doi.org/10.1002/rmv.2265]
[13]
Safi, S.; Korang, S.K.; Nielsen, E.E.; Sethi, N.J.; Feinberg, J.; Gluud, C.; Jakobsen, J.C. Beta-blockers for heart failure. Cochrane Database Syst. Rev., 2017, (12), CD012897.
[http://dx.doi.org/10.1002/14651858.CD012897] [PMID: 34739733]
[14]
Larochelle, P. Tobe, S.W.; Lacourcière, Y. β-blockers in hypertension: Studies and meta-analyses over the years. Can. J. Cardiol., 2014, 30(5)(Suppl.), S16-S22.
[http://dx.doi.org/10.1016/j.cjca.2014.02.012] [PMID: 24750978]
[15]
Xu, T. Huang, Y.; Zhou, H.; Bai, Y.; Huang, X.; Hu, Y.; Xu, D.; Zhang, Y.; Zhang, J. β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation-a meta-analysis. BMC Cardiovasc. Disord., 2019, 19(1), 135.
[http://dx.doi.org/10.1186/s12872-019-1079-2] [PMID: 31159740]
[16]
Vasanthakumar, N. Beta-adrenergic blockers as a potential treatment for COVID-19 patients. BioEssays, 2020, 42(11), e2000094.
[http://dx.doi.org/10.1002/bies.202000094] [PMID: 32815593]
[17]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7), e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[18]
Margulis, A.V.; Pladevall, M.; Riera-Guardia, N.; Varas-Lorenzo, C.; Hazell, L.; Berkman, N.D.; Viswanathan, M.; Perez-Gutthann, S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa Scale and the RTI item bank. Clin. Epidemiol., 2014, 6, 359-368.
[http://dx.doi.org/10.2147/CLEP.S66677] [PMID: 25336990]
[19]
An, C.; Lim, H.; Kim, D.W.; Chang, J.H.; Choi, Y.J.; Kim, S.W. Machine learning prediction for mortality of patients diagnosed with COVID-19: A nationwide Korean cohort study. Sci. Rep., 2020, 10(1), 18716.
[http://dx.doi.org/10.1038/s41598-020-75767-2] [PMID: 33127965]
[20]
Ayed, M.; Borahmah, A.A.; Yazdani, A.; Sultan, A.; Mossad, A.; Rawdhan, H. Assessment of clinical characteristics and mortality-associated factors in COVID-19 Critical cases in Kuwait. Med. Princ. Pract., 2021, 30(2), 185-192.
[http://dx.doi.org/10.1159/000513047] [PMID: 33197912]
[21]
Cariou, B.; Hadjadj, S.; Wargny, M.; Pichelin, M.; Al-Salameh, A.; Allix, I.; Amadou, C.; Arnault, G.; Baudoux, F.; Bauduceau, B.; Borot, S.; Bourgeon-Ghittori, M.; Bourron, O.; Boutoille, D.; Cazenave-Roblot, F.; Chaumeil, C.; Cosson, E.; Coudol, S.; Darmon, P.; Disse, E.; Ducet-Boiffard, A.; Gaborit, B.; Joubert, M.; Kerlan, V.; Laviolle, B.; Marchand, L.; Meyer, L.; Potier, L.; Prevost, G.; Riveline, J.P.; Robert, R.; Saulnier, P.J.; Sultan, A.; Thébaut, J.F.; Thivolet, C.; Tramunt, B.; Vatier, C.; Roussel, R.; Gautier, J.F.; Gourdy, P. CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study. Diabetologia, 2020, 63(8), 1500-1515.
[http://dx.doi.org/10.1007/s00125-020-05180-x] [PMID: 32472191]
[22]
Choi, M.H.; Ahn, H.; Ryu, H.S.; Kim, B.J.; Jang, J.; Jung, M.; Kim, J.; Jeong, S.H. Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea. J. Clin. Med., 2020, 9(6), 1959.
[http://dx.doi.org/10.3390/jcm9061959] [PMID: 32585855]
[23]
Chouchana, L.; Beeker, N.; Garcelon, N.; Rance, B.; Paris, N.; Salamanca, E. Association of antihypertensive agents with the risk of in-hospital death in patients with COVID-19. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.11.23.20237362]
[24]
Conversano, A.; Melillo, F.; Napolano, A.; Fominskiy, E.; Spessot, M.; Ciceri, F.; Agricola, E. Renin-angiotensin-aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: A case series study. Hypertension, 2020, 76(2), e10-e12.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15312] [PMID: 32383626]
[25]
Dashti, H.T.; Bates, D.; Fiskio, J.M.; Roche, E.C.; Mora, S.; Demler, O. Clinical characteristics and severity of COVID-19 disease in patients from boston area hospitals. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.07.27.20163071]
[26]
de Abajo, F.J.; Rodríguez-Martín, S.; Lerma, V.; Mejía-Abril, G.; Aguilar, M.; García-Luque, A.; Laredo, L.; Laosa, O.; Centeno-Soto, G.A.; Ángeles Gálvez, M.; Puerro, M.; González-Rojano, E.; Pedraza, L.; de Pablo, I.; Abad-Santos, F.; Rodríguez-Mañas, L.; Gil, M.; Tobías, A.; Rodríguez-Miguel, A.; Rodríguez-Puyol, D.; Barreira-Hernandez, D.; Zubiaur, P.; Santos-Molina, E.; Pintos-Sánchez, E.; Navares-Gómez, M.; Aparicio, R.M.; García-Rosado, V.; Gutiérrez-Ortega, C.; Pérez, C.; Ascaso, A.; Elvira, C. MED-ACE2-COVID-19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. Lancet, 2020, 395(10238), 1705-1714.
[http://dx.doi.org/10.1016/S0140-6736(20)31030-8] [PMID: 32416785]
[27]
El-Solh, A.A.; Meduri, U.G.; Lawson, Y.; Carter, M.; Mergenhagen, K.A. Clinical course and outcome of COVID-19 acute respiratory distress syndrome: Data from a national repository. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.10.16.20214130]
[28]
Ferguson, J.; Rosser, J.I.; Quintero, O.; Scott, J.; Subramanian, A.; Gumma, M.; Rogers, A.; Kappagoda, S. Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, Northern California, USA, march-april 2020. Emerg. Infect. Dis., 2020, 26(8), 1679-1685.
[http://dx.doi.org/10.3201/eid2608.201776] [PMID: 32407284]
[29]
Fletcher, R.A.; Matcham, T.; Tiburcio, M.; Anisimovich, A.; Jovanovic, S.; Albergante, L. Risk factors for clinical progression in patients with COVID-19: A retrospective study of electronic health record data in the United Kingdom. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.05.11.20093096]
[30]
Genet, B.; Vidal, J.S.; Cohen, A.; Boully, C.; Beunardeau, M.; Marine Harlé, L.; Gonçalves, A.; Boudali, Y.; Hernandorena, I.; Bailly, H.; Lenoir, H.; Piccoli, M.; Chahwakilian, A.; Kermanach, L.; de Jong, L.; Duron, E.; Girerd, X.; Hanon, O. COVID-19 in-hospital mortality and use of renin-angiotensin system blockers in geriatrics patients. J. Am. Med. Dir. Assoc., 2020, 21(11), 1539-1545.
[http://dx.doi.org/10.1016/j.jamda.2020.09.004] [PMID: 33138935]
[31]
Giacomelli, A.; Ridolfo, A.L.; Milazzo, L.; Oreni, L.; Bernacchia, D.; Siano, M.; Bonazzetti, C.; Covizzi, A.; Schiuma, M.; Passerini, M.; Piscaglia, M.; Coen, M.; Gubertini, G.; Rizzardini, G.; Cogliati, C.; Brambilla, A.M.; Colombo, R.; Castelli, A.; Rech, R.; Riva, A.; Torre, A.; Meroni, L.; Rusconi, S.; Antinori, S.; Galli, M. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol. Res., 2020, 158, 104931.
[http://dx.doi.org/10.1016/j.phrs.2020.104931] [PMID: 32446978]
[32]
Gupta, A.; Madhavan, M.V.; Poterucha, T.J.; DeFilippis, E.M.; Hennessey, J.A.; Redfors, B.; Eckhardt, C.; Bikdeli, B.; Platt, J.; Nalbandian, A.; Elias, P. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat. Commun., 2021, 12(1), 1-9.
[http://dx.doi.org/10.21203/rs.3.rs-56210/v1]
[33]
Hippisley-Cox, J.; Young, D.; Coupland, C.; Channon, K.M.; Tan, P.S.; Harrison, D.A.; Rowan, K.; Aveyard, P.; Pavord, I.D.; Watkinson, P.J. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. Heart, 2020, 106(19), 1503-1511.
[http://dx.doi.org/10.1136/heartjnl-2020-317393] [PMID: 32737124]
[34]
Iaccarino, G.; Grassi, G.; Borghi, C.; Ferri, C.; Salvetti, M.; Volpe, M.; Cicero, A.F.G.; Minuz, P.; Muiesan, M.L.; Mulatero, P.; Mulè, G.; Pucci, G.; Savoia, C.; Sechi, L.; Carugo, S.; Fallo, F.; Giannattasio, C.; Grassi, D.; Letizia, C.; Perlini, S.; Rizzoni, D.; Sarzani, R.; Tocci, G.; Veglio, F.; Agabiti Rosei, C.; Bevilacqua, M.; Bisogni, V.; Bombelli, M.; Bulfone, L.; Canichella, F.; Carpani, G.; Catanuso, M.; Chiarini, G.; Chiumiento, F.; Cianci, R.; Cipollini, F.; Concistrè, A.; Dalbeni, A.; De Blasi, R.A.; De Ciuceis, C.; Dell’Oro, R.; Di Guardo, A.; Di Lorenzo, S.; Di Norcia, M.; Ervo, R.; Eula, E.; Fabbricatore, D.; Fanelli, E.; Fava, C.; Grasso, E.; Grimaldi, A.; Illario, M.; Invernizzi, C.; Iraca, E.; Liegi, F.; Malerba, P.; Maloberti, A.; Mancusi, C.; Molinari, G.; Mussinelli, R.; Paini, A.; Pellimassi, P.; Piazza, O.; Pontremoli, R.; Quarti Tevano, F.; Rabbia, F.; Rocco, M.; Sabena, A.; Salinaro, F.; Schiavi, P.; Sgariglia, M.C.; Spannella, F.; Tedeschi, S.; Viale, P. SARS-RAS Investigators. Age and multimorbidity predict death among COVID-19 patients: Results of the SARS-RAS study of the italian society of hypertension. Hypertension, 2020, 76(2), 366-372.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15324] [PMID: 32564693]
[35]
Khawaja, A.P.; Warwick, A.N.; Hysi, P.G.; Kastner, A.; Dick, A. Khaw, PT Associations with COVID-19 hospitalisation amongst 406,793 adults: The UK Biobank prospective cohort study. medRxiv, 2020.
[36]
Khider, L.; Gendron, N.; Goudot, G.; Chocron, R.; Hauw-Berlemont, C.; Cheng, C.; Rivet, N.; Pere, H.; Roffe, A.; Clerc, S.; Lebeaux, D.; Debuc, B.; Veyer, D.; Rance, B.; Gaussem, P.; Bertil, S.; Badoual, C.; Juvin, P.; Planquette, B.; Messas, E.; Sanchez, O.; Hulot, J.S.; Diehl, J.L.; Mirault, T.; Smadja, D.M. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J. Thromb. Haemost., 2020, 18(9), 2391-2399.
[http://dx.doi.org/10.1111/jth.14968] [PMID: 32558198]
[37]
Kim, J.; Kim, D.W.; Kim, K.I.; Kim, H.B.; Kim, J.H.; Lee, Y.G.; Byeon, K.H.; Cheong, H.K. Korean Society of Hypertension. Compliance of antihypertensive medication and risk of coronavirus disease 2019: A cohort study using big data from the Korean national health insurance service. J. Korean Med. Sci., 2020, 35(25), e232.
[http://dx.doi.org/10.3346/jkms.2020.35.e232] [PMID: 32597045]
[38]
Kocayigit, I; Kocayigit, H; Yaylaci, S; Can, Y; Erdem, AF; Karabay, O Impact of antihypertensive agents on clinical course and in-hospital mortality: Analysis of 169 hypertensive patients hospitalized for COVID-19. Rev Assoc Med Bras, 1992, 66Suppl(Suppl 2), 71-76.
[39]
Kolin, D.A.; Kulm, S.; Elemento, O. Clinical and genetic characteristics of COVID-19 patients from UK biobank. medRxiv, 2020.
[40]
Lafaurie, M.; Martin-Blondel, G.; Delobel, P.; Charpentier, S.; Sommet, A.; Moulis, G. Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACE-CoV study. Fundam. Clin. Pharmacol., 2020, 36(Suppl. 1), S123-S31.
[http://dx.doi.org/10.1111/fcp.12613] [PMID: 33111329]
[41]
Lee, J.; Jo, S.J.; Cho, Y.; Lee, J.H.; Oh, I.Y.; Park, J.J. Effects of renin-angiotensin system blockers on the risk and outcomes of SARS-CoV-2 infection in patients with hypertension. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.), 2021, 36(Suppl. 1), S123-S131.
[http://dx.doi.org/10.3904/kjim.2020.390] [PMID: 32872731]
[42]
Liabeuf, S.; Moragny, J.; Bennis, Y.; Batteux, B.; Brochot, E.; Schmit, J.L. Association between renin-angiotensin system inhibitors and COVID-19 complications. Eur. Heart J. Cardiovasc. Pharmacother., 2021, 7(5), 426-434.
[43]
Mancia, G.; Rea, F.; Ludergnani, M.; Apolone, G.; Corrao, G. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N. Engl. J. Med., 2020, 382(25), 2431-2440.
[http://dx.doi.org/10.1056/NEJMoa2006923] [PMID: 32356627]
[44]
McCarthy, C.P.; Murphy, S.; Jones-O’Connor, M.; Olshan, D.S.; Khambhati, J.R.; Rehman, S.; Cadigan, J.B.; Cui, J.; Meyerowitz, E.A.; Philippides, G.; Friedman, L.S.; Kadar, A.Y.; Hibbert, K.; Natarajan, P.; Massaro, A.F.; Bohula, E.A.; Morrow, D.A.; Woolley, A.E.; Januzzi, J.L., Jr; Wasfy, J.H. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine, 2020, 26, 100504.
[http://dx.doi.org/10.1016/j.eclinm.2020.100504] [PMID: 32838244]
[45]
McKeigue, P.M.; Kennedy, S.; Weir, A.; Bishop, J.; McGurnaghan, S.J.; McAllister, D. Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study. medRxiv, 2020.
[46]
Nguyen, A.B.; Upadhyay, G.A.; Chung, B.; Smith, B.; Besser, S.A.; Johnson, J.A. Outcomes and cardiovascular comorbidities in a predominantly african-american population with COVID-19. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.06.28.20141929]
[47]
Poblador-Plou, B.; Carmona-Pírez, J.; Ioakeim-Skoufa, I.; Poncel-Falcó, A.; Bliek-Bueno, K.; Cano-Del Pozo, M.; Gimeno-Feliú, L.A.; González-Rubio, F.; Aza-Pascual-Salcedo, M.; Bandrés-Liso, A.C.; Díez-Manglano, J.; Marta-Moreno, J.; Mucherino, S.; Gimeno-Miguel, A.; Prados-Torres, A. EpiChron Group. Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: Results from the precovid study in Spain. Int. J. Environ. Res. Public Health, 2020, 17(14), 5171.
[http://dx.doi.org/10.3390/ijerph17145171] [PMID: 32709002]
[48]
Polverino, F.; Stern, D.A.; Ruocco, G.; Balestro, E.; Bassetti, M.; Candelli, M.; Cirillo, B.; Contoli, M.; Corsico, A.; D’Amico, F.; D’Elia, E.; Falco, G.; Gasparini, S.; Guerra, S.; Harari, S.; Kraft, M.; Mennella, L.; Papi, A.; Parrella, R.; Pelosi, P.; Poletti, V.; Polverino, M.; Tana, C.; Terribile, R.; Woods, J.C.; Di Marco, F.; Martinez, F.D. ItaliCO study group Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (italico). Front. Cardiovasc. Med., 2020, 7, 5 85866.
[http://dx.doi.org/10.3389/fcvm.2020.585866] [PMID: 33195473]
[49]
Reilev, M.; Kristensen, K.B.; Pottegård, A.; Lund, L.C.; Hallas, J.; Ernst, M.T.; Christiansen, C.F.; Sørensen, H.T.; Johansen, N.B.; Brun, N.C.; Voldstedlund, M.; Støvring, H.; Thomsen, M.K.; Christensen, S.; Gubbels, S.; Krause, T.G.; Mølbak, K.; Thomsen, R.W. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: A nationwide cohort. Int. J. Epidemiol., 2020, 49(5), 1468-1481.
[http://dx.doi.org/10.1093/ije/dyaa140] [PMID: 32887982]
[50]
Reynolds, H.R.; Adhikari, S.; Pulgarin, C.; Troxel, A.B.; Iturrate, E.; Johnson, S.B.; Hausvater, A.; Newman, J.D.; Berger, J.S.; Bangalore, S.; Katz, S.D.; Fishman, G.I.; Kunichoff, D.; Chen, Y.; Ogedegbe, G.; Hochman, J.S. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N. Engl. J. Med., 2020, 382(25), 2441-2448.
[http://dx.doi.org/10.1056/NEJMoa2008975] [PMID: 32356628]
[51]
Rezel-Potts, E.; Douiri, A.; Chowienczyk, P.J. Gulliford, MC Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom. medRxiv, 2020.
[52]
Selçuk, M. Çınar, T.; Keskin, M.; Çiçek, V.; Kılıç, l. Kenan, B.; Doğan, S.; Asal, S.; Günay, N.; Yıldırım, E.; Keskin, Ü.; Orhan, A.L. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in COVID-19 pneumonia patients? Clin. Exp. Hypertens., 2020, 42(8), 738-742.
[http://dx.doi.org/10.1080/10641963.2020.1783549] [PMID: 32569491]
[53]
Sourij, H.; Aziz, F.; Bräuer, A.; Ciardi, C.; Clodi, M.; Fasching, P. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes. Metab., 2020, 23(2), 589-598.
[http://dx.doi.org/10.1111/dom.14256] [PMID: 33200501]
[54]
Ullah, A.Z.M.D.; Sivapalan, L.; Chelala, C.; Kocher, H.M. COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: A single-centre cohort study. medRxiv, 2020.
[55]
Vila-Corcoles, A.; Satue-Gracia, E.; Ochoa-Gondar, O.; Torrente-Fraga, C.; Gomez-Bertomeu, F.; Vila-Rovira, A.; Hospital-Guardiola, I.; de Diego-Cabanes, C.; Bejarano-Romero, F.; Rovira-Veciana, D.; Basora-Gallisa, J. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. J. Clin. Hypertens. (Greenwich), 2020, 22(8), 1379-1388.
[http://dx.doi.org/10.1111/jch.13948] [PMID: 32710674]
[56]
Vrillon, A.; Hourregue, C.; Azuar, J.; Grosset, L.; Boutelier, A.; Tan, S.; Roger, M.; Mourman, V.; Mouly, S.; Sène, D.; François, V.; Dumurgier, J.; Paquet, C. for LRB COVID Group. COVID-19 in older adults: A series of 76 patients aged 85 years and older with COVID-19. J. Am. Geriatr. Soc., 2020, 68(12), 2735-2743.
[http://dx.doi.org/10.1111/jgs.16894] [PMID: 33045106]
[57]
Wang, B.; Van Oekelen, O.; Mouhieddine, T.H.; Del Valle, D.M.; Richter, J.; Cho, H.J.; Richard, S.; Chari, A.; Gnjatic, S.; Merad, M.; Jagannath, S.; Parekh, S.; Madduri, D. A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. J. Hematol. Oncol., 2020, 13(1), 94.
[http://dx.doi.org/10.1186/s13045-020-00934-x] [PMID: 32664919]
[58]
Yahyavi, A.; Hemmati, N.; Derakhshan, P.; Banivaheb, B.; Karimi Behnagh, A.; Tofighi, R. TehraniYazdi, A.; Kabir, A. Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: A retrospective cohort study. Intern. Emerg. Med., 2020, 1-11.
[http://dx.doi.org/10.1007/s11739-020-02523-9] [PMID: 33085063]
[59]
Yan, F.; Huang, F.; Xu, J.; Yang, P.; Qin, Y.; Lv, J.; Zhang, S.; Ye, L.; Gong, M.; Liu, Z.; Wei, J.; Xie, T.; Xu, K.F.; Gao, G.F.; Wang, F.S.; Cai, L.; Jiang, C. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov., 2020, 6(1), 77.
[http://dx.doi.org/10.1038/s41421-020-00221-6] [PMID: 33298897]
[60]
Yan, H.; Valdes, A.M.; Vijay, A.; Wang, S.; Liang, L.; Yang, S.; Wang, H.; Tan, X.; Du, J.; Jin, S.; Huang, K.; Jiang, F.; Zhang, S.; Zheng, N.; Hu, Y.; Cai, T.; Aithal, G.P. Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: A large case-control study. Clin. Pharmacol. Ther., 2020, 108(6), 1185-1194.
[http://dx.doi.org/10.1002/cpt.2047] [PMID: 32910830]
[61]
Yuan, Y.; Liu, D.; Zeng, S.; Wang, S.; Xu, S.; Wang, Y.; Yu, R.; Gao, Y.; Li, H.; Feng, X.; Zhou, N.; Zhao, C.; Gao, Q. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension. J. Infect., 2020, 81(5), 816-846.
[http://dx.doi.org/10.1016/j.jinf.2020.08.014] [PMID: 32800800]
[62]
Hariyanto, T.I.; Putri, C.; Arisa, J.; Situmeang, R.F.V.; Kurniawan, A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis. Arch. Gerontol. Geriatr., 2021, 93, 104299.
[http://dx.doi.org/10.1016/j.archger.2020.104299] [PMID: 33285424]
[63]
Putri, C.; Hariyanto, T.I.; Hananto, J.E.; Christian, K.; Situmeang, R.F.V.; Kurniawan, A. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression. Parkinsonism Relat. Disord., 2021, S1353- 8020(21), 00152-158.
[http://dx.doi.org/10.1016/j.parkreldis.2021.04.019]
[64]
Siahaan, Y.M.T.; Hartoyo, V.; Hariyanto, T.I.; Kurniawan, A. Coronavirus disease 2019 (COVID-19) outcomes in patients with sarcopenia: A meta-analysis and meta-regression. Clin. Nutr. ESPEN, 2022.
[http://dx.doi.org/10.1016/j.clnesp.2022.01.016]
[65]
Aiello, A.; Farzaneh, F.; Candore, G.; Caruso, C.; Davinelli, S.; Gambino, C.M.; Ligotti, M.E.; Zareian, N.; Accardi, G. Immunosenescence and its hallmarks: How to oppose aging strategically? a review of potential options for therapeutic intervention. Front. Immunol., 2019, 10, 2247.
[http://dx.doi.org/10.3389/fimmu.2019.02247] [PMID: 31608061]
[66]
Lanza, K.; Perez, L.G.; Costa, L.B.; Cordeiro, T.M.; Palmeira, V.A.; Ribeiro, V.T.; Simões, E. Silva, A.C. COVID-19: The renin-angiotensin system imbalance hypothesis. Clin. Sci. (Lond.), 2020, 134(11), 1259-1264.
[http://dx.doi.org/10.1042/CS20200492] [PMID: 32507883]
[67]
De Miguel, C.; Rudemiller, N.P.; Abais, J.M.; Mattson, D.L. Inflammation and hypertension: New understandings and potential therapeutic targets. Curr. Hypertens. Rep., 2015, 17(1), 507.
[http://dx.doi.org/10.1007/s11906-014-0507-z] [PMID: 25432899]
[68]
Dorian, P. Angaran, P. β-blockers and atrial fibrillation: Hypertension and other medical conditions influencing their use. Can. J. Cardiol., 2014, 30(5)(Suppl.), S38-S41.
[http://dx.doi.org/10.1016/j.cjca.2013.09.029] [PMID: 24530215]
[69]
Somer, M.; Kallio, J.; Pesonen, U.; Pyykkö, K.; Huupponen, R.; Scheinin, M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol., 2000, 49(6), 549-554.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00197.x] [PMID: 10848718]
[70]
Agarwal, S.; Agarwal, S.K. Lopinavir-Ritonavir in SARS-CoV-2 infection and drug-drug interactions with cardioactive medications. Cardiovasc. Drugs Ther., 2021, 35(3), 427-440.
[http://dx.doi.org/10.1007/s10557-020-07070-1] [PMID: 32918656]
[71]
Khalid, M.M.; Galuska, M.A.; Hamilton, R.J. Beta-Blocker Toxicity; StatPearls: Treasure Island, FL, 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448097/
[72]
Wang, Y.; Wang, Z.; Tse, G.; Zhang, L.; Wan, E.Y.; Guo, Y.; Lip, G.Y.H.; Li, G.; Lu, Z.; Liu, T. Cardiac arrhythmias in patients with COVID-19. J. Arrhythm., 2020, 36(5), 827-836.
[http://dx.doi.org/10.1002/joa3.12405] [PMID: 33024460]
[73]
Morales, D.R.; Lipworth, B.J.; Donnan, P.T.; Jackson, C.; Guthrie, B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: Population-based nested case control study. BMC Med., 2017, 15(1), 18.
[http://dx.doi.org/10.1186/s12916-017-0781-0] [PMID: 28126029]
[74]
Bharati, S.M.; Singh, N. Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients. J. Pharmacol. Pharmacother., 2016, 7(2), 80-86.
[http://dx.doi.org/10.4103/0976-500X.184771] [PMID: 27440952]
[75]
Poirier, L.; Cléroux, J.; Nadeau, A.; Lacourcière, Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens., 2001, 19(8), 1429-1435.
[http://dx.doi.org/10.1097/00004872-200108000-00011] [PMID: 11518851]
[76]
Sachdeva, S.; Desai, R.; Gupta, U.; Prakash, A.; Jain, A.; Aggarwal, A. Admission hyperglycemia in non-diabetics predicts mortality and disease severity in COVID-19: A pooled analysis and meta-summary of literature. SN Compr. Clin. Med., 2020, 2(11), 2161-2166.
[http://dx.doi.org/10.1007/s42399-020-00575-8] [PMID: 33073173]
[77]
Dungan, K.; Merrill, J.; Long, C.; Binkley, P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc. Diabetol., 2019, 18(1), 163.
[http://dx.doi.org/10.1186/s12933-019-0967-1] [PMID: 31775749]
[78]
Al-Kuraishy, H.M.; Al-Gareeb, A.I.; Mostafa-Hedeab, G.; Kasozi, K.I.; Zirintunda, G.; Aslam, A.; Allahyani, M.; Welburn, S.C.; Batiha, G.E. Effects of β-blockers on the sympathetic and cytokines storms in COVID-19. Front. Immunol., 2021, 127, 49291.
[http://dx.doi.org/10.3389/fimmu.2021.749291] [PMID: 34867978]
[79]
Clemente-Moragón, A.; Martínez-Milla, J.; Oliver, E.; Santos, A.; Flandes, J.; Fernández, I.; Rodríguez-González, L.; Serrano Del Castillo, C.; Ioan, A.M.; López-Álvarez, M.; Gómez-Talavera, S.; Galán-Arriola, C.; Fuster, V.; Pérez-Calvo, C.; Ibáñez, B. Metoprolol in critically Ill patients with COVID-19. J. Am. Coll. Cardiol., 2021, 78(10), 1001-1011.
[http://dx.doi.org/10.1016/j.jacc.2021.07.003] [PMID: 34474731]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy